TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02199431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study: NCT02309320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0171

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02153177

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair
Description: Arthroscopic procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair
Description: Arthroscopic procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole
Description: In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/Acetaminophen
Description: Hydrocodone/Acetaminophen is given for pain control after the surgery.
Study: NCT03302169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy with posterior rhabdosphincter reconstruction
Description: To suture the Denonvilliers fascia and bladder to the median dorsal raphe according to Rocco technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical prostatectomy without posterior rhabdosphincter reconstruction
Description: Standard technique with a running suture to perform the urethrovesical anastomosis
Study: NCT03004781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting program
Study: NCT03195829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Stimulation
Description: The intervention group performed 12-week, 90-minutes per week of cognitive stimulation in group using a tablet with a commercial software with specific exercises to train the cognitive functioning and promote the relation ties in group-session.The program's difficulty level was adjusted to the MMSE score, and was gradually increased.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multimedia-based internet
Description: The active control group had access to different Multimedia contents (travel, photos, music, TV program, cooking recipes) using a tablet, 90-minutes per week each week during 3-months. Each group session was centered in a particular topic, participants were able to select different media free available in Internet.
Study: NCT01356823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30μg HPV
Description: Participants would intramuscularly receive 30μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60μg HPV
Description: Participants would intramuscularly receive 60μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
Study: NCT02312739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-office Transcervical Sterilization (Essure®)
Description: The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: In-office Transcervical Sterilization (Essure®)
Description: The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oral pain medications
Description: one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular Ketorolac
Description: 30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Ketorolac
Description: 30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pills
Description: Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen at 5L/min given to patients randomized to the active comparator arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm
Study: NCT03555890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine IRT 5 mg
Description: Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine ODT 5 mg
Description: Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine ODT 5 mg
Description: Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine ODT 5 mg
Description: Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine ODT 5 mg
Description: Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.
Study: NCT05436691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information and Coping with Anxiety Training
Description: Informing and Coping with Anxiety Training was given to the experimental group before the operation through a prepared booklet.The information booklet about the training was created by the researchers by reviewing the current literature. The booklet provides information for patients scheduled for hysterectomy about how to cope with surgery-related anxiety. The booklet provides information on what the hysterectomy is, why it is performed, what risks it has, what should be done before, during and after the hysterectomy, what rules the patient should comply with after hysterectomy, in which cases she should present to the health institution, what changes she might experience in her social, physical, sexual and emotional life after the surgery. The booklet also provides information about discharge training and coping with anxiety.
Study: NCT01356823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90μg HPV
Description: Participants would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Participants would intramuscularly receive 10μg of hepatitis B vaccine at 0, 1, 6 month for 3 doses.
Study: NCT02365441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib
Study: NCT01697748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silver-impregnated dressing
Description: Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Telfa pad dressing
Description: Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
Study: NCT03894826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat 100 MG
Description: Vorinostat administered by mouth, once daily at a dose of 230 mg/m2/day for a total of 6 weeks
Study: NCT00093912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium nitroprusside
Study: NCT03468660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory training with feedback
Description: Experimental group receives phoneme-level and sentence-level training with feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Listening paradigm with no feedback
Description: Active controls listen to acoustic stimuli with no feedback
Study: NCT00448266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified Cyclophophamide, Carboplatin and Thiotepa
Description: 2 courses of Intensified Cyclophophamide, Carboplatin and Thiotepa with PBPC support
Study: NCT03456869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Specific Implant
Description: The patient specific implant is used to simultaneously complete the reposition and fixation of the chin.
Study: NCT03615079

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavioral therapy
Description: An 8-week, internet-based cognitive behavioral therapy (CBT) program for depression
Study: NCT04190238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Super inductive system (high frequency electromagnetic field)
Description: Super inductive system (high frequency electromagnetic field)
Study: NCT01889537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The patient will receive virtual reality during a burn care procedure
Study: NCT00448266

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dose dense adriamycine and cyclophosphamide
Description: dose dense adriamycine and cyclophosphamide, Q 2 weeks
Study: NCT04190238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Super inductive system (high frequency electromagnetic field)
Description: Super inductive system (high frequency electromagnetic field)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: specific for spasticity
Study: NCT00513695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study: NCT03827499

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB dietary supplementation
Description: Intervention groups including HMB supplementation (Ex-HMB and NoEx-HMB) will receive a 3 g daily dose of free acid HMB in powder form dissolved freely into 250 mL of water during a 24-week intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB dietary supplementation
Description: Intervention groups including HMB supplementation (Ex-HMB and NoEx-HMB) will receive a 3 g daily dose of free acid HMB in powder form dissolved freely into 250 mL of water during a 24-week intervention
Study: NCT02385448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
Study: NCT04190238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: specific for spasticity
Study: NCT02385448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microgynon
Description: The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
Study: NCT01753024

Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral nutrition (EN)
Description: All patients enrolled in this study must carry out nutritional support by enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral nutrition (EN)
Description: All patients enrolled in this study must carry out nutritional support by enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral nutrition (EN)
Description: All patients enrolled in this study must carry out nutritional support by enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral nutrition (EN)
Description: All patients enrolled in this study must carry out nutritional support by enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral nutrition (EN)
Description: All patients enrolled in this study must carry out nutritional support by enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral nutrition (EN)
Description: All patients enrolled in this study must carry out nutritional support by enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral nutrition (EN)
Description: All patients enrolled in this study must carry out nutritional support by enteral nutrition

Intervention type: DIETARY_SUPPLEMENT
Intervention: Enteral nutrition (EN)
Description: All patients enrolled in this study must carry out nutritional support by enteral nutrition
Study: NCT05935501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formaderm Young
Description: Dermal filler injection to facial areas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Dermal filler injection to facial areas.
Study: NCT03722160

Intervention type: DEVICE
Group type: OTHER
Intervention: Solo TympanostomyTube Device
Description: The Solo Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
Study: NCT03360461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMI-137
Description: EMI-137 - a fluorescent c-Met receptor targeted peptide
Study: NCT02553330

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ruxolitinib Phosphate Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate Cream
Study: NCT02945865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain assessment
Description: Pain assessment with assessment tools
Study: NCT03403725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN1309
Description: MEN1309 solution for intravenous infusion once every 3 weeks
Study: NCT04100447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.
Study: NCT00373334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nizatidine (axid)
Description: nizatidine (axid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nizatidine (axid)
Description: nizatidine (axid)
Study: NCT01114542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
Study: NCT00373334

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01659021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Description: Administered intravenously
Study: NCT01812837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aminolevulinic Acid
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Blue light
Description: Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Blue light
Description: Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
Study: NCT01114542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
Study: NCT05319340

Intervention type: OTHER
Group type: OTHER
Intervention: prescribing anticoagulant therapy
Description: Patients who need anticoagulants were consulted by a cardiologist with subsequent recommendations
Study: NCT03571854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group PCV-VG
Description: Pressure controlled ventilation-volume guaranteed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group VCV
Description: Volume controlled ventilation
Study: NCT04926896

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional iliac crest bone harvesting surgery
Description: The experimental group and the control group do not have special requirements; perform the surgery according to the normal operation methods of different sites.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive bone harvesting surgery
Description: Minimally invasive bone harvesting surgery
Study: NCT01928654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropulse laser treatment
Description: Device for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser modified ETDRS
Description: Device for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.
Study: NCT03793075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine 5 mcg/kg/min will be used as intravenous anesthetic infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: propofol 17 mcg /kg/min
Study: NCT03210233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood test, skin testing and challenge testing.
Description: Skin Prick Testing (SPT) and Intradermal Testing (IDT). We will follow the STARD framework for reporting studies of diagnostic accuracy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood test, skin testing and challenge testing.
Description: Skin Prick Testing (SPT) and Intradermal Testing (IDT). We will follow the STARD framework for reporting studies of diagnostic accuracy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood test, skin testing and challenge testing.
Description: Skin Prick Testing (SPT) and Intradermal Testing (IDT). We will follow the STARD framework for reporting studies of diagnostic accuracy